The FDA has accepted Navidea Biopharmaceuticals' ($NAVB) latest supplemental new drug application to expand the use of its Lymphoseek injectable diagnostic imaging agent to track more kinds of cancers. Two sNDA's are now pending with regulators. One seeks to use the agent to help detect and map the spread of head and neck cancer. This latest application would enable more flexible Lymphoseek use for lymphatic mapping and lymphoscintigraphy imaging. Navidea Chief Medical Officer Cornelia Reininger said in a statement that the SNDA's, if approved, could help "address important areas of unmet medical need." Item